Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: HAIC-GEMOX+Cadonilimab+Regorafenib

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT06335927

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Anlotinib
Drug: Trastuzumab deruxtecan

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 42

Registration Number: NCT06331169

Locations: 🇨🇳
Jian Zhang, Shanghai, Shanghai, China

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Phase 3

Not yet recruiting

Conditions: Chemotherapy-induced Nausea and Vomiting
Highly Emetogenic Chemotherapy

Interventions: Drug: Netupitant / Palonosetron Oral Capsule [Akynzeo]
Drug: Olanzapine
Drug: Dexamethasone Oral

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Fudan University

Target Recruit Count: 627

Registration Number: NCT06331520

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3

Not yet recruiting

Conditions: Lung Cancer
EGFR Gene Mutation
Minimal Residual Disease

Interventions: Drug: No adjuvant therapy
Drug: Osimertinib

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Fudan University

Target Recruit Count: 226

Registration Number: NCT06323148

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

Phase 2

Recruiting

Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions: Drug: Sintilimab+Pegaspargase
Drug: P-GemOx
Drug: GELAD
Radiation: IMRT

First Posted Date: 2024-03-18

Last Posted Date: 2025-05-06

Lead Sponsor: Fudan University

Target Recruit Count: 210

Registration Number: NCT06314334

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: QL1706
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Bevacizumab

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT06313970

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

Phase 2

Recruiting

Conditions: NSCLC Stage IV

Interventions: Radiation: SBRT or LDRT
Drug: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy

First Posted Date: 2024-03-15

Last Posted Date: 2024-06-05

Lead Sponsor: Fudan University

Target Recruit Count: 146

Registration Number: NCT06313541

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Metronomic Capecitabine in Stage III Gastric Cancer

Phase 3

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: Metronomic capecitabine group
Other: Observation

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-08

Lead Sponsor: Fudan University

Target Recruit Count: 722

Registration Number: NCT06313567

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Not Applicable

Not yet recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Fudan University

Target Recruit Count: 63

Registration Number: NCT06313554

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Phase 2

Not yet recruiting

Conditions: Colon Cancer

Interventions: Drug: Everolimus
Drug: PD-1

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT06301386

Locations: 🇨🇳
Anyang Tumor Hospital, Anyang, Henan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy